Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
With
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed stage IV or recurrent NSCLC of squamous or non-squamous histology that is not amenable to therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
No prior treatment with systemic anti-cancer therapy for Stage IV disease.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to1.
Measurable disease by computed tomography or magnetic resonance imaging per RECIST v1.1.
Documentation of program death ligand-1 (PD-L1) status of 0 to 49% by IHC performed by the central laboratory prior to randomization.
You may not be if
Known epidermal growth factor receptor (EGFR) mutations sensitive to available targeted inhibitor therapy.
Known ALK or ROS1 rearrangements sensitive to available targeted inhibitor therapy.
Untreated central nervous system (CNS) metastases.
Unevaluable PD-L1 status or PD-L1 status of ≥ 50% by IHC performed by a central laboratory.
Carcinomatous meningitis.
Active, known or suspected autoimmune disease.
Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, IDO1 targeted agent, or any other antibody or drug targeting T cell co-stimulation or checkpoint pathways.
History of allergy or hypersensitivity to platinum-containing compounds or study drug components.
Physical and laboratory test findings outside the protocol-defined range.
Clareo Health | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
